Imunon (IMNN) grants director 6,934 shares instead of cash board fees

Rhea-AI Filing Summary

Fritz Frederick J. reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. director Fritz Frederick J. received an equity compensation grant of 6,934 shares of Common Stock on 2026-07-31. The shares were granted in lieu of cash for a portion of his board fees at a value of $1.59 per share. Following this non-derivative, directly owned award, his reported Common Stock holdings increased to 21,031 shares.

Insider Trade Summary

Net Buyer: 6,934 shares

Net Buy 1 txn

Insider Fritz Frederick J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,934	$1.59	$11K

Holdings After Transaction: Common Stock — 21,031 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of board fees.

Key Figures

Shares granted: 6,934 shares Grant price: $1.59 per share Shares owned after: 21,031 shares

3 metrics

Shares granted 6,934 shares Common Stock granted to director on 2026-07-31

Grant price $1.59 per share Value assigned to the Common Stock grant on 2026-07-31

Shares owned after 21,031 shares Director’s direct Common Stock holdings following the grant

Key Terms

non-derivative, Grant, award, or other acquisition, Stock granted in lieu of cash

3 terms

non-derivative financial

"The transaction type is reported as non-derivative Common Stock."

Grant, award, or other acquisition financial

"Transaction code A is described as Grant, award, or other acquisition."

Stock granted in lieu of cash financial

"Footnote F1 states: Stock granted in lieu of cash for portion of board fees."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:16 PM Accepted by SEC EDGAR 08/04/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did Imunon (IMNN) report for director Fritz Frederick J.?

Imunon reported that director Fritz Frederick J. received a grant of 6,934 shares of Common Stock on 2026-07-31. The award was classified as a grant, award, or other acquisition rather than an open-market purchase or sale.

How many Imunon (IMNN) shares were granted and at what value?

The director was granted 6,934 shares of Imunon Common Stock valued at $1.59 per share. This value is used to quantify the equity compensation received in place of part of his normal cash board fees.

Why did Imunon (IMNN) grant stock instead of cash to the director?

According to the footnote, the shares were “stock granted in lieu of cash for portion of board fees.” This means a portion of the director’s board compensation was paid in equity instead of cash, aligning part of pay with shareholder interests.

What are Fritz Frederick J.’s Imunon (IMNN) holdings after this grant?

After the award, the director’s reported direct holdings increased to 21,031 shares of Imunon Common Stock. This figure reflects his position immediately following the 6,934-share non-derivative grant on 2026-07-31.

Is the Imunon (IMNN) director’s stock grant a derivative or non-derivative transaction?

The reported transaction is classified as non-derivative Common Stock. It represents an equity grant, not the exercise or conversion of options or other derivative securities, and is held as direct ownership by the director.

Does the Imunon (IMNN) Form 4 indicate any stock sales by the director?

No stock sales are reported in this Form 4. The filing shows only an acquisition of 6,934 shares as a grant in lieu of cash board fees, with no dispositions or sales listed for the same date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fritz Frederick J.

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		A		6,934(1)	A	$1.59	21,031	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees.

	/s/ Susan Eylward, Attorney-in-Fact for Frederick J. Fritz	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)